Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Bosch, Almudena ^a   Bertran, Silvina P ^a   Lu, Yongke ^a   Garcia, Avalon ^a   Jones, Alexis M ^a   Dawson, Marcia I ^b   Farias, Eduardo F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; ANTINEOPLASTIC AGENT; CELLULAR RETINOL BINDING PROTEIN 1; CYTOCHROME P450 26A1; PROTEIN P27; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR ALPHA AGONIST; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; UNCLASSIFIED DRUG; UVOMORULIN; BENZOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOL BINDING PROTEIN; SMALL INTERFERING RNA; TETRALIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER MODEL; CELL DEATH; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG METASTASIS; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; TRANSGENIC MOUSE; TUMOR GROWTH; UPREGULATION; AGONISTS; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; LUNG TUMOR; METABOLISM; ONCOGENE MYC; SECONDARY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BENZOATES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; RECEPTORS, RETINOIC ACID; RETINOL-BINDING PROTEINS; RNA, SMALL INTERFERING; TETRAHYDRONAPHTHALENES; TRANSCRIPTION, GENETIC;

EID: 84865281435     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3247     Document Type: Article

References (78)

1. Dolle P. Developmental expression of retinoic acid receptors (RARs). Nucl Recept Signal 2009, 7:e006. 2686085, 19471585.
2. Han YH, Zhou H, Kim JH, Yan TD, Lee KH, Wu H, Lin F, Lu N, Liu J, Zeng JZ, Zhang XK. A unique cytoplasmic localization of RARgamma and its regulations. J Biol Chem 2009, 284:18503-14. 10.1074/jbc.M109.007708, 2709335, 19416983.
3. Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, Chambon P. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med 2006, 203:1283-1293. 10.1084/jem.20052105, 2121209, 16682494.
4. Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS, Dmitrovsky E. Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. Oncogene 1998, 16:3471-3480. 10.1038/sj.onc.1201876, 9692555.
5. Astrom A, Pettersson U, Krust A, Chambon P, Voorhees JJ. Retinoic acid and synthetic analogs differentially activate retinoic acid receptor dependent transcription. Biochem Biophys Res Commun 1990, 173:339-345. 10.1016/S0006-291X(05)81062-9, 2175182.
6. Mark M, Ghyselinck NB, Chambon P. Function of retinoic acid receptors during embryonic development. Nucl Recept Signal 2009, 7:e002. 2670431, 19381305.
7. Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol 2006, 46:451-480. 10.1146/annurev.pharmtox.46.120604.141156, 16402912.
8. Lohnes D, Mark M, Mendelsohn C, Dolle P, Decimo D, LeMeur M, Dierich A, Gorry P, Chambon P. Developmental roles of the retinoic acid receptors. J Steroid Biochem Mol Biol 1995, 53:475-486. 10.1016/0960-0760(95)00094-G, 7626498.
9. Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal 2009, 7:e005. 2686084, 19471584.
10. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. International Union of Pharmacology. LXIII. Retinoid × receptors. Pharmacol Rev 2006, 58:760-772. 10.1124/pr.58.4.7, 17132853.
11. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006, 58:712-725. 10.1124/pr.58.4.4, 17132850.
12. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997, 278:1073-1077. 10.1126/science.278.5340.1073, 9353183.
13. Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 1997, 57:2642-2650.
14. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R, Bollag W. Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 1997, 70:619-627. 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6, 9052765.
15. Fontana JA, Hobbs PD, Dawson MI. Inhibition of mammary carcinoma growth by retinoidal benzoic acid derivatives. Exp Cell Biol 1988, 56:254-263.
16. Donato LJ, Noy N. Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling. Cancer Res 2005, 65:8193-8199. 10.1158/0008-5472.CAN-05-1177, 16166294.
17. Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC, Zhang X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 1996, 16:1138-1149. 231096, 8622658.
18. Seewaldt VL, Kim JH, Caldwell LE, Johnson BS, Swisshelm K, Collins SJ. All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ 1997, 8:631-641.
19. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35:1332-1338.
20. Moon RC, Mehta RG. Chemoprevention of experimental carcinogenesis in animals. Prev Med 1989, 18:576-591. 10.1016/0091-7435(89)90031-5, 2694156.
21. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D, Sigman CC, Boone CW, Kelloff GJ. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 1994, 20:32-54.
22. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
23. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76:1704-1709.
24. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010, 10:775-783. 10.1038/nrc2943, 20966922.
25. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001, 6:377-388. 10.1023/A:1011342220621, 11483862.
26. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB, Sporn MB. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994, 54:4614-4617.
27. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther 2004, 4:180-188. 10.1586/14737140.4.2.180, 15056048.
28. Rigas JR, Dragnev KH. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 2005, 10:22-33. 10.1634/theoncologist.10-1-22, 15632250.
29. Dragnev KH, Petty WJ, Ma Y, Rigas JR, Dmitrovsky E. Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer 2005, 6:237-244. 10.3816/CLC.2005.n.003, 15694016.
30. Chiba H, Clifford J, Metzger D, Chambon P. Specific and redundant functions of retinoid × Receptor/Retinoic acid receptor heterodimers in differentiation, proliferation, and apoptosis of F9 embryonal carcinoma cells. J Cell Biol 1997, 139:735-747. 10.1083/jcb.139.3.735, 2141719, 9348290.
31. Gillespie RF, Gudas LJ. Retinoic acid receptor isotype specificity in F9 teratocarcinoma stem cells results from the differential recruitment of coregulators to retinoic response elements. J Biol Chem 2007, 282:33421-33434. 10.1074/jbc.M704845200, 17875646.
32. Husmann M, Lehmann J, Hoffmann B, Hermann T, Tzukerman M, Pfahl M. Antagonism between retinoic acid receptors. Mol Cell Biol 1991, 11:4097-4103. 361221, 1649387.
33. Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta 2011, 1812:1023-1031. 10.1016/j.bbadis.2010.10.007, 20970498.
34. Chytil F, Ong DE. Cellular retinol- and retinoic acid-binding proteins in vitamin A action. Fed Proc 1979, 38:2510-2514.
35. Burns LL, Ropson IJ. Folding of intracellular retinol and retinoic acid binding proteins. Proteins 2001, 43:292-302. 10.1002/prot.1040, 11288179.
36. Li E, Norris AW. Structure/function of cytoplasmic vitamin A-binding proteins. Annu Rev Nutr 1996, 16:205-234. 10.1146/annurev.nu.16.070196.001225, 8839926.
37. Napoli JL, Boerman MH, Chai X, Zhai Y, Fiorella PD. Enzymes and binding proteins affecting retinoic acid concentrations. J Steroid Biochem Mol Biol 1995, 53:497-502. 10.1016/0960-0760(95)00096-I, 7626500.
38. Yan TD, Wu H, Zhang HP, Lu N, Ye P, Yu FH, Zhou H, Li WG, Cao X, Lin YY, He JY, Gao WW, Zhao Y, Xie L, Chen JB, Zhang XK, Zeng JZ. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res 2010, 70:2285-2295. 10.1158/0008-5472.CAN-09-2968, 20197465.
39. Lu Y, Bertran S, Samuels TA, Mira-y-Lopez R, Farias EF. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. Oncogene 2010, 29:3665-3676. 10.1038/onc.2010.119, 2891995, 20453882.
40. Delescluse C, Cavey MT, Martin B, Bernard BA, Reichert U, Maignan J, Darmon M, Shroot B. Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol 1991, 40:556-562.
41. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733. 10.1016/j.cell.2007.02.050, 1948722, 17512406.
42. Farias EF, Marzan C, Mira-y-Lopez R. Cellular retinol-binding protein-I inhibits PI3K/Akt signaling through a retinoic acid receptor-dependent mechanism that regulates p85-p110 heterodimerization. Oncogene 2005, 24:1598-1606. 10.1038/sj.onc.1208347, 15608670.
43. Farias EF, Ong DE, Ghyselinck NB, Nakajo S, Kuppumbatti YS, Mira y Lopez R. Cellular retinol-binding protein I, a regulator of breast epithelial retinoic acid receptor activity, cell differentiation, and tumorigenicity. J Natl Cancer Inst 2005, 97:21-29. 10.1093/jnci/dji004, 15632377.
44. Chen Y, Olopade OI. MYC in breast tumor progression. Expert Rev Anticancer Ther 2008, 8:1689-1698. 10.1586/14737140.8.10.1689, 3027840, 18925859.
45. Grandori C, Eisenman RN. Myc target genes. Trends Biochem Sci 1997, 22:177-181. 10.1016/S0968-0004(97)01025-6, 9175477.
46. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000, 16:653-699. 10.1146/annurev.cellbio.16.1.653, 11031250.
47. Claassen GF, Hann SR. Myc-mediated transformation: the repression connection. Oncogene 1999, 18:2925-2933. 10.1038/sj.onc.1202747, 10378689.
48. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003, 3:219-231. 10.1016/S1535-6108(03)00030-8, 12676581.
49. Dimberg A, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines. Leuk Lymphoma 2003, 44:1641-1650. 10.1080/1042819031000083316, 14692514.
50. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268. 10.1016/S1046-2023(03)00032-X, 12798140.
51. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004, 24:8541-8555. 10.1128/MCB.24.19.8541-8555.2004, 516765, 15367674.
52. Smith WC, Nakshatri H, Leroy P, Rees J, Chambon P. A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter. EMBO J 1991, 10:2223-2230. 452911, 1648481.
53. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 2003, 109:80-88. 10.1016/S1521-6616(03)00208-0, 14585279.
54. Orlando FA, Brown KD. Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol 2009, 16:2270-2279. 10.1245/s10434-009-0500-y, 19452229.
55. Borriello A, Bencivenga D, Criscuolo M, Caldarelli I, Cucciolla V, Tramontano A, Borgia A, Spina A, Oliva A, Naviglio S, Della Regione F. Targeting p27Kip1 protein: its relevance in the therapy of human cancer. Expert Opin Ther Targets 2011, 15:677-693. 10.1517/14728222.2011.561318, 21355788.
56. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011, 27:347-376. 10.1146/annurev-cellbio-092910-154036, 21740232.
57. Dawson MI, Zhang XK. Discovery and design of retinoic acid receptor and retinoid × receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr Med Chem 2002, 9:623-637.
58. Peterson VJ, Barofsky E, Deinzer ML, Dawson MI, Feng KC, Zhang XK, Madduru MR, Leid M. Mass-spectrometric analysis of agonist-induced retinoic acid receptor gamma conformational change. Biochem J 2002, 362:173-181. 10.1042/0264-6021:3620173, 1222374, 11829754.
59. Lu M, Mira-y-Lopez R, Nakajo S, Nakaya K, Jing Y. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells. Oncogene 2005, 24:4362-4369. 10.1038/sj.onc.1208661, 15870697.
60. Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 1988, 31:2182-2192. 10.1021/jm00119a021, 3184125.
61. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284. 10.1038/nrc2622, 19308067.
62. Eskild W, Troen G, Blaner WS, Nilsson A, Hansson V. Evidence for independent control at the mRNA and protein levels of cellular retinol binding protein 1 in rat Sertoli cells. J Reprod Fertil 2000, 119:101-109.
63. Sun SY, Yue P, Chandraratna RA, Tesfaigzi Y, Hong WK, Lotan R. Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. Mol Pharmacol 2000, 58:508-514.
64. Rishi AK, Zhang L, Boyanapalli M, Wali A, Mohammad RM, Yu Y, Fontana JA, Hatfield JS, Dawson MI, Majumdar AP, Reicher U. Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. J Biol Chem 2003, 278:33422-33435. 10.1074/jbc.M303173200, 12816952.
65. Farhana L, Dawson MI, Leid M, Wang L, Moore DD, Liu G, Xia Z, Fontana JA. Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor. Cancer Res 2007, 67:318-325. 10.1158/0008-5472.CAN-06-2164, 2833172, 17210713.
66. Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao M, Garattini E. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 2011, 31:3431-43.
67. Chambon P. A decade of molecular biology of retinoic acid receptors. Faseb J 1996, 10:940-954.
68. Mengeling BJ, Goodson ML, Bourguet W, Privalsky ML. SMRTepsilon, a corepressor variant, interacts with a restricted subset of nuclear receptors, including the retinoic acid receptors alpha and beta. Mol Cell Endocrinol 2012, 351:306-316. 10.1016/j.mce.2012.01.006, 22266197.
69. Amat R, Gudas LJ. RARgamma is required for correct deposition and removal of Suz12 and H2A.Z in embryonic stem cells. J Cell Physiol 2011, 226:293-298. 10.1002/jcp.22420, 3369573, 20857416.
70. Kirmizis A, Bartley SM, Farnham PJ. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003, 2:113-121.
71. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010, 39:761-772. 10.1016/j.molcel.2010.08.013, 2938080, 20832727.
72. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874. 10.1038/nature04431, 16357870.
73. Arapshian A, Bertran S, Kuppumbatti YS, Nakajo S, Mira YLR. Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. Mol Cancer 2004, 3:13. 10.1186/1476-4598-3-13, 419713, 15113415.
74. Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Waxman S, Mira YLR. Cellular retinol-binding protein expression and breast cancer. J Natl Cancer Inst 2000, 92:475-480. 10.1093/jnci/92.6.475, 10716965.
75. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004, 6:577-586. 10.1016/j.ccr.2004.10.013, 15607962.
76. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000, 7:143-164. 10.1677/erc.0.0070143, 11021963.
77. Watson PH, Safneck JR, Le K, Dubik D, Shiu RP. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 1993, 85:902-907. 10.1093/jnci/85.11.902, 8492318.
78. Shiu RP, Watson PH, Dubik D. c-myc oncogene expression in estrogen-dependent and -independent breast cancer. Clin Chem 1993, 39:353-355.